10-Q: Kestra Medical Technologies Reports Q2 Loss Amid Revenue Growth

Kestra Medical Technologies, Ltd. reported a 53% revenue increase for the quarter ended October 31, 2025, driven by patient growth, but also saw a significant rise in net loss and identified material weaknesses in internal controls.

Summary

• Revenue for the three months ended October 31, 2025, increased by $7.9 million, or 53%, to $22.6 million, compared to $14.7 million for the same period in 2024, primarily due to a 54% increase in patients using the ASSURE WCD.
• Gross profit for the three months ended October 31, 2025, increased by 96% to $11.4 million, up from $5.8 million in the prior year, driven by revenue growth and a 20% decrease in cost of revenues per patient.
• Net loss for the three months ended October 31, 2025, increased by 59% to $(32.8) million, compared to $(20.6) million for the same period in 2024.
• Selling, general and administrative expenses for the three months ended October 31, 2025, surged by 79% to $38.3 million, primarily due to increased personnel expenses, legal, accounting, and professional service fees related to operating as a public company.
• Cash and cash equivalents stood at $175.4 million as of October 31, 2025, down from $237.6 million on April 30, 2025.
• The company incurred negative operating cash flows of $(44.6) million for the six months ended October 31, 2025, compared to $(35.6) million for the same period in 2024.
• Material weaknesses in internal control over financial reporting were identified, including insufficient resources in accounting, finance, and IT, ineffective controls for complex transactions, and inadequate IT general controls.
• A subsequent public offering on December 4, 2025, raised net proceeds of $149.2 million by issuing 6,900,000 common shares at $23.00 per share.

Sentiment

Score: 4

Explanation: The company exhibits strong revenue and gross profit growth, indicating market traction for its product. However, this growth is accompanied by significantly increased net losses and operating cash burn, reflecting heavy investment in commercialization and public company costs. The identified material weaknesses in internal controls are a notable concern, though remediation is underway. The recent capital raise provides a strong liquidity buffer, but profitability remains a distant goal.

Positives

• Strong revenue growth of 53% for both the three and six months ended October 31, 2025, indicating increasing market adoption of the ASSURE WCD.
• Gross profit increased by 96% for the three months and 102% for the six months ended October 31, 2025, demonstrating improved operational efficiency and utilization of medical equipment.
• Cost of revenues per patient decreased by 20% for both periods, attributed to better utilization of the rental pool, lower disposable costs from volume, and manufacturing cost improvement programs.
• Successful completion of a public underwritten offering on December 4, 2025, raising $149.2 million in net proceeds, significantly bolstering liquidity.
• Interest income increased substantially by $0.9 million for the three months and $3.0 million for the six months ended October 31, 2025, due to higher cash balances in interest-bearing accounts.

Negatives

• Net loss increased by 59% to $(32.8) million for the three months and by 43% to $(58.6) million for the six months ended October 31, 2025.
• Operating expenses, particularly Selling, General and Administrative (SG&A), increased significantly by 79% for the three months and 77% for the six months, driven by headcount increases and public company costs.
• Net cash used in operating activities increased to $(44.6) million for the six months ended October 31, 2025, from $(35.6) million in the prior year, indicating higher cash burn.
• Accumulated deficit grew to $(578.9) million as of October 31, 2025, reflecting continued losses since inception.
• Identified material weaknesses in internal control over financial reporting, including insufficient resources, ineffective controls for complex transactions, and IT general control deficiencies.

Risks

• Ability to continue expanding commercialization of the ASSURE WCD and future product candidates.
• Maintaining existing and obtaining new regulatory approvals for product distribution in new markets.
• Rate and degree of market acceptance of the ASSURE WCD or any future product candidates.
• Availability and adequacy of reimbursement for products from third-party payors.
• Ability to scale manufacturing, obtain sufficient and timely supplies of components, and effectively manage inventory and distribution.
• Ability to hire and retain qualified personnel, including senior management and sales professionals.
• Accuracy of estimates for total addressable market and near-term achievable market.
• Timing or likelihood of regulatory filings and approvals or clearances.
• Execution of growth plans, including entry into new markets.
• Ability to establish and maintain intellectual property protection or defend against infringement claims.
• Progress, timing, costs, and results of clinical trials.
• Changes and developments relating to the regulatory landscape.
• Financial performance and changes in market trends.
• Increased expenses associated with operating as a public company.
• Changes and developments relating to competitors and the industry.
• Potential for lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, requiring additional funding.
• Material weaknesses in internal control over financial reporting could lead to material misstatements in financial statements.

Future Outlook

The company expects to continue incurring net losses in the foreseeable future as it scales its business and invests in its commercial organization. Existing cash and cash equivalents, including proceeds from the IPO and subsequent public offering, along with cash generated from revenue, are believed to be sufficient to fund operating and capital needs for at least the next 12 months. However, there is a risk that lower-than-expected cash generation or higher-than-expected expenses may necessitate additional funding through future equity and debt financings.

Management Comments

• Management believes that existing cash and cash equivalents, including net proceeds from the IPO, as well as cash generated from revenue transactions with customers, will be sufficient to fund operating and capital needs for at least the next 12 months.
• Management cannot predict with certainty that adequate funding will be available on acceptable terms or at all, and failure to obtain sufficient funds could materially and adversely affect the business.
• Management is making progress towards remediating identified material weaknesses in internal control over financial reporting, including hiring additional personnel and engaging third parties for assistance.

Industry Context

Kestra Medical Technologies operates in the medical device and digital healthcare sector, specifically focusing on cardiovascular disease with its Wearable Cardioverter Defibrillator (WCD) and Cardiac Recovery System platform. The WCD market in the United States has established reimbursement codes from Medicare, Medicaid, and private payors, which is crucial for revenue generation. The company's growth is tied to increasing market acceptance and penetration of its next-generation WCD, which it believes offers significant clinical and functional advantages, including reduced false alarms and improved wearability, potentially disrupting the existing market and expanding the addressable market.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is from time to time a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business. Management does not expect any of its pending legal proceedings to have a material adverse effect on its results of operations, financial position, or cash flows.

Related Party Transactions

• West Affum Holdings, L.P. (direct parent prior to IPO) was involved in capital contributions, including the issuance of redeemable preferred stock for $103.4 million in May and July 2024.
• West Affum Holdings, L.P. issued a warrant to the lender of the Term Loan 2024 on September 29, 2023, which was later cancelled and exchanged for a new warrant (2033 Warrant) to purchase Kestra Medical Technologies, Ltd. Common Shares.

Stakeholder Impact

• Shareholders: Experience dilution from recent and subsequent public offerings but benefit from increased liquidity and funding for growth. Face risks associated with ongoing losses and internal control issues.
• Employees: Increased headcount to support commercial growth, participation in equity incentive plans, and new executive appointments.
• Customers/Patients: Continued commercialization and development of the ASSURE WCD and Cardiac Recovery System platform, aiming to improve patient outcomes.
• Creditors: The company is in compliance with all financial covenants related to its Term Loan 2024.
• Regulatory Authorities: The company is addressing identified material weaknesses in internal controls and continues to comply with SEC filing requirements.

Next Steps

• Continue to scale the business and increase the size of the commercial team to market the Cardiac Recovery System platform in the United States.
• Invest in research and development activities to develop new products and services, and enhance existing ones.
• Conduct clinical trials as necessary and prepare new products and services for commercialization.
• Remediate identified material weaknesses in internal control over financial reporting by hiring additional personnel, engaging third parties, designing and implementing controls for complex transactions, and enhancing IT governance processes.

Key Dates

Recommendation

Kestra Medical Technologies demonstrates strong top-line growth and improved gross margins, indicating increasing market acceptance for its ASSURE WCD. However, the company continues to incur substantial net losses and negative operating cash flow as it invests heavily in commercial expansion and R&D. The identified material weaknesses in internal controls are a significant concern, requiring diligent remediation. While the recent capital raise provides a solid financial runway, the path to profitability and resolution of control issues introduces considerable uncertainty. A 'hold' recommendation is appropriate for investors monitoring the company's ability to translate revenue growth into sustainable profitability and strengthen its internal governance.

Keywords

Medical device, Wearable Cardioverter Defibrillator, WCD, Cardiac Recovery System, ASSURE WCD, Kestra Medical Technologies, Financial results, SEC filing, 10-Q, Internal controls, Public offering, Cardiovascular disease